Cargando…

Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation

Optimization of injected gallium-68 ((68)Ga) activity for (68)Ga-prostate-specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) studies is relevant for image quality, radiation protection, and from an economic point of view. However, no clear guidelines are...

Descripción completa

Detalles Bibliográficos
Autores principales: Wielaard, J., Habraken, J. B. A., Brinks, P., Lavalaye, J., Boellaard, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158971/
https://www.ncbi.nlm.nih.gov/pubmed/32297142
http://dx.doi.org/10.1186/s40658-020-00289-9
_version_ 1783522586239434752
author Wielaard, J.
Habraken, J. B. A.
Brinks, P.
Lavalaye, J.
Boellaard, R.
author_facet Wielaard, J.
Habraken, J. B. A.
Brinks, P.
Lavalaye, J.
Boellaard, R.
author_sort Wielaard, J.
collection PubMed
description Optimization of injected gallium-68 ((68)Ga) activity for (68)Ga-prostate-specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) studies is relevant for image quality, radiation protection, and from an economic point of view. However, no clear guidelines are available for (68)Ga-PSMA studies. Therefore, a phantom study is performed to determine the highest coefficient of variation (COV) acceptable for reliable image interpretation and quantification. To evaluate image interpretation, the relationship of COV and contrast-to-noise ratio (CNR) was studied. The CNR should remain larger than five, according to the Rose criterion. To evaluate image quantification, the effect of COV on the percentage difference (PD) between quantification results of two studies was analyzed. Comparison was done by calculating the PD of the SUV(max). The maximum allowable PD(SUVmax) was set at 20%. The highest COV at which both criteria are still met is defined as COV(max). Of the NEMA Image Quality phantom, a 20 min/bed (2 bed positions) scan was acquired in list-mode PET (Philips Gemini TF PET/CT). The spheres to background activity ratio was approximately 9:1. To obtain images with different COV, lower activity was mimicked by reconstructions with acquisition times of 10 min/bed to 5 s/bed. Pairs of images were obtained by reconstruction of two non-overlapping parts of list-mode data. For the 10-mm diameter sphere, a COV of 25% still meets the criteria of CNR(SUVmean) ≥ 5 and PD(SUVmax) ≤ 20%. This phantom scan was acquired with an acquisition time of 116 s and a background activity concentration of 0.71 MBq/kg. Translation to a clinical protocol results in a clinical activity regimen of 3.5 MBq/kg min at injection. To verify this activity regimen, 15 patients (6 MBq/kg min) with a total of 22 lesions are included. Additional reconstructions were made to mimic the proposed activity regimen. Based on the CNR(SUVmax), no lesions were missed with this proposed activity regimen. For our institution, a clinical activity regimen of 3.5 MBq/kg min at injection is acceptable, which indicates that activity can be reduced by almost 50% compared with the current code of practice. Our proposed method could be used to obtain an objective activity regimen for other PET/CT systems and tracers.
format Online
Article
Text
id pubmed-7158971
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-71589712020-04-23 Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation Wielaard, J. Habraken, J. B. A. Brinks, P. Lavalaye, J. Boellaard, R. EJNMMI Phys Original Research Optimization of injected gallium-68 ((68)Ga) activity for (68)Ga-prostate-specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) studies is relevant for image quality, radiation protection, and from an economic point of view. However, no clear guidelines are available for (68)Ga-PSMA studies. Therefore, a phantom study is performed to determine the highest coefficient of variation (COV) acceptable for reliable image interpretation and quantification. To evaluate image interpretation, the relationship of COV and contrast-to-noise ratio (CNR) was studied. The CNR should remain larger than five, according to the Rose criterion. To evaluate image quantification, the effect of COV on the percentage difference (PD) between quantification results of two studies was analyzed. Comparison was done by calculating the PD of the SUV(max). The maximum allowable PD(SUVmax) was set at 20%. The highest COV at which both criteria are still met is defined as COV(max). Of the NEMA Image Quality phantom, a 20 min/bed (2 bed positions) scan was acquired in list-mode PET (Philips Gemini TF PET/CT). The spheres to background activity ratio was approximately 9:1. To obtain images with different COV, lower activity was mimicked by reconstructions with acquisition times of 10 min/bed to 5 s/bed. Pairs of images were obtained by reconstruction of two non-overlapping parts of list-mode data. For the 10-mm diameter sphere, a COV of 25% still meets the criteria of CNR(SUVmean) ≥ 5 and PD(SUVmax) ≤ 20%. This phantom scan was acquired with an acquisition time of 116 s and a background activity concentration of 0.71 MBq/kg. Translation to a clinical protocol results in a clinical activity regimen of 3.5 MBq/kg min at injection. To verify this activity regimen, 15 patients (6 MBq/kg min) with a total of 22 lesions are included. Additional reconstructions were made to mimic the proposed activity regimen. Based on the CNR(SUVmax), no lesions were missed with this proposed activity regimen. For our institution, a clinical activity regimen of 3.5 MBq/kg min at injection is acceptable, which indicates that activity can be reduced by almost 50% compared with the current code of practice. Our proposed method could be used to obtain an objective activity regimen for other PET/CT systems and tracers. Springer International Publishing 2020-04-15 /pmc/articles/PMC7158971/ /pubmed/32297142 http://dx.doi.org/10.1186/s40658-020-00289-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Wielaard, J.
Habraken, J. B. A.
Brinks, P.
Lavalaye, J.
Boellaard, R.
Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation
title Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation
title_full Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation
title_fullStr Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation
title_full_unstemmed Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation
title_short Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation
title_sort optimization of injected (68)ga-psma activity based on list-mode phantom data and clinical validation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158971/
https://www.ncbi.nlm.nih.gov/pubmed/32297142
http://dx.doi.org/10.1186/s40658-020-00289-9
work_keys_str_mv AT wielaardj optimizationofinjected68gapsmaactivitybasedonlistmodephantomdataandclinicalvalidation
AT habrakenjba optimizationofinjected68gapsmaactivitybasedonlistmodephantomdataandclinicalvalidation
AT brinksp optimizationofinjected68gapsmaactivitybasedonlistmodephantomdataandclinicalvalidation
AT lavalayej optimizationofinjected68gapsmaactivitybasedonlistmodephantomdataandclinicalvalidation
AT boellaardr optimizationofinjected68gapsmaactivitybasedonlistmodephantomdataandclinicalvalidation